Loading patent…
AssigneesTianjin University, Hainan Lingkang Pharmaceutical Co., Ltd
InventorsHongxun HAO, Linggang TAO, Fang He, Baohong HOU, Jingkang WANG, Jun LV, Qiuxiang YIN, Yongli WANG, Junbo GONG, Chuang XIE, Ying Bao
Estimating the term…
A novel crystalline form is defined by diffraction angle 2θ° of X-ray powder diffraction pattern and characteristic peak of differential scanning calorimetry (DSC). The novel crystalline form of Cefamandole Nafate is prepared as follows: adding Cefamandole Nafate in solid state to an organic solvent to form a suspension with a concentration of 0.04˜0.3 g/ml, stirring the suspension at 40˜50° C. for a period of time, and then cooling to 5˜15° C. at certain cooling rate, continuing to stir for a period of time, then suction filtrating the obtained suspension, the resulting filer cake is Cefamandole Nafate as wet product, which is dried to constant weight to provide the novel crystalline form of Cefamandole Nafate as final product.
A crystalline form of Cefamandole Nafate, characterized in that, it has an X-ray powder diffraction pattern having characteristic peaks expressed in degrees 2θ at 4.0±0.2, 4.7±0.2, 6.2±0.2, 7.5±0.2, 9.9±0.2, 10.8±0.2, 14.5±0.2, 15.8±0.2, 16.3±0.2, 17.4±0.2, 18.1±0.2, 19.2±0.2, 20.1±0.2, 21.4±0.2, 22.2±0.2, 22.8±0.2, 23.9±0.2, 24.9±0.2, 30.1±0.2, and 34.1±0.2.
Dependencies are inferred from the claim text.